上海魁特迪生物科技

Shanghai Quatidi Biotechnology is a specialized drug discovery firm headquartered in the Zhangjiang Hi-Tech Park of Shanghai, China. Established in 2016, the company focuses on the identification and optimization of novel small molecule therapeutics through its advanced high-throughput screening (HTS) platform. Quatidi operates as a hybrid entity, offering contract research services (CRO) to global pharmaceutical clients while simultaneously developing an internal pipeline of first-in-class and best-in-class candidates. Their primary therapeutic focus includes metabolic diseases, such as diabetes and obesity, and various oncology indications. The company is led by a team of industry veterans with extensive experience in medicinal chemistry and early-stage drug development.